Figure 8.
Effect of proteasome inhibitor on established human breast cancer cell (MDA-MB-231-GFP) tumor xenograft. Subcutaneous tumors were generated by injecting 1 × 107 MDA-MB-231-GFP cells into the flanks of nude mice. Tumors were established for 10 days before the initiation of therapy. Representative images were taken under microscope at the end of week 3 of therapy and show results for (a) vehicle-treated controls, (b) Bortezomib-treated mice and (c) BU-32-treated mice. Doses of 0.02 and 0.06 mg/kg body weight were used for Bortezomib and BU-32. (d) Tumor volumes were measured 1, 2, and 3 weeks after initiation of therapy. Results are mean ± standard deviation (n = 10).